Japanese Pharmaceutical Companies Show Interest to Conduct Clinical Trials in Malaysia

TOKYO, 6 November 2018 – Clinical Research Malaysia (CRM) hold a half-day seminar that targets Japanese pharmaceutical and medical device companies interested in conducting clinical trials in the Asian region. This is the first time for CRM to deliver a clinical trial seminar focusing on its home country in Japan.

Read more

Embracing Digital Health

L-R: YBrs. Dr. Kalaiarasu M. Periasamy, Deputy Director, National Clinical Research Centre, Y.Bhg. Datuk Dr. Shahnaz Murad, Deputy General-Director of Health Malaysia (Research & Technical Support), YB. Dr. Lee Boon Chye, Deputy Minister of Health, YBrs. Dr. Akhmal Yusof, CEO of Clinical Research Malaysia, YBhg. Dato’ Dr. Goh Pik Pin, Director National Clinical Research Malaysia

KUALA LUMPUR, 24 September 2018 – The 12thNational Conference for Clinical Research (NCCR) brought together medical experts and researchers under one platform to understand the way digital technology can impact the Malaysian healthcare delivery system, thus potentially improving patient outcomes.

Read more

Celebrating Clinical Research Through the Clinical Trials Day 2018 & 2nd IKN Research Day

PUTRAJAYA, 5 September 2018 – Clinical Trials Day 2018 was held at the Institut Kanser Negara (IKN), its second time since its initiation last year, to celebrate patients, volunteers and medical professionals involved in clinical trials. Clinical Research Malaysia (CRM) partnered with Clinical Research Centre (CRC) and IKN to organise this momentous event in conjunction of IKN’s 5th anniversary.

Read more

Clinical Research Malaysia Forms Two Global Partnerships and New Foreign Investments

L-R: Dr. Akhmal Yusof (CEO of CRM), Mr. Zabidi Mahbar (Executive Director of Strategic Planning (Manufacturing), Malaysian Investment Development Authority (MIDA), YBhg Datuk Dr. Noor Hisham Abdullah (Director General of Health, Malaysia), Dr. Hytham Al-Masri (President & CEO of Hematogenix) and Dr. Yooni Kim (Executive Director, Asia Operations, Novotech)

PUTRAJAYA, 20 April 2018 – Hematogenix, a global leader in integrated laboratory services, and Novotech, Australia’s largest independent contract research organization (CRO) have both signed a Memorandum of Understanding with Clinical Research Malaysia (CRM) to establish strategic partnerships in clinical research.

Read more

Clinical Research Malaysia Sets New Partnership In Japan

TOKYO, 23 March 2018 – intellim Corporation and Clinical Research Malaysia (CRM) have signed a Memorandum of Understanding (MoU) to establish a new strategic partnership between both companies in clinical research. The inking of this MoU spells out support on clinical research activities in both Malaysia and Japan, as well as in business development and networking opportunities for both organizations.

Read more

Encouraging New Clinical Research Collaborations between Malaysia & China

Hangzhou, 30 January – The First Affiliated Hospital of Zhejiang University and Clinical Research Malaysia (CRM) have signed a Memorandum of Understanding (MoU) to collaborate in clinical trial activities in Malaysia and China, today.

The First Affiliated Hospital of Zhejiang University is one of the oldest university in China with a long history in medical research and development. With this cooperation, both parties will provide support and valuable resources to encourage new clinical research collaborations. In addition, it opens teaching and training opportunities, this is also in line with the one belt one road policy which benefit both countries.

Read more

Clinical Research Malaysia Signs Corruption-Free Pledge with MACC

LANGKAWI, 22 Jan – Clinical Research Malaysia (CRM), represented by 140 of its staff, signed the Corruption-Free Pledge with the MACC in a ceremony held at Berjaya Langkawi Resort today.

The signing and pledge ceremony was led by the CEO of CRM, Dr. Akhmal Yusof and witnessed by KPKPj Tuan Ruslan Tuan Mat, Deputy Director of the MACC Community Education Division.

Read more

Ministry of Health Malaysia and The Drugs for Neglected Diseases initiative (DNDi)

Clinical Research Malaysia and the Drugs for Neglected Diseases initiative Sign Agreement to Launch Clinical Studies for a Public Health Approach to Hepatitis C in Malaysia

[Putrajaya, 13 January 2016] The Drugs for Neglected Diseases initiative (DNDi) and the Ministry of Health of the Government of Malaysia have agreed to work together to develop a public health approach to Hepatitis C within the framework of the future National Strategic Plan on viral hepatitis. The immediate goal is to conduct clinical studies of promising new treatment regimens for Hepatitis C, to be followed by scale-up of treatment for patients, with the overall objective of ensuring equitable access to affordable and effective treatments for patients suffering from this disease in Malaysia.

Read more